Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors.
Celecoxib, is a selective cyclooxygenase-2 (COX2) inhibitor with a 1,5-diaryl pyrazole scaffold. Celecoxib has a better safety profile compared to other COX2 inhibitors having side effects of systemic hypertension and thromboembolic complications. This may be partly attributed to an off-target activity involving phosphodiesterase 5 (PDE5) inhibition and the potentiation of NO/cGMP signalling allowing coronary vasodilation and aortic relaxation. Inspired by the structure of celecoxib, we synthesized a chemically diverse series of compounds containing a 1,3,5-trisubstituted pyrazoline scaffold to improve PDE5 inhibitory potency, while eliminating COX2 inhibitory activity. SAR studies for PDE5 inhibition revealed an essential role for a carboxylic acid functionality at the 1-phenyl and the importance of the non-planar pyrazoline core over the planar pyrazole with the 5-phenyl moiety tolerating a range of substituents. These modifications led to new PDE5 inhibitors with approximately 20-fold improved potency to inhibit PDE5 and no COX-2 inhibitory activity compared with celecoxib. PDE isozyme profiling of compound 11 revealed a favorable selectivity profile. These results suggest that trisubstituted pyrazolines provide a promising scaffold for further chemical optimization to identify novel PDE5 inhibitors with potential for less side effects compared with available PDE5 inhibitors used for the treatment of penile erectile dysfunction and pulmonary hypertension.
['Abdel-Halim|Mohammad|M|', 'Tinsley|Heather|H|', 'Keeton|Adam B|AB|', 'Weam|Mohammed|M|', 'Atta|Noha H|NH|', 'Hammam|Mennatallah A|MA|', 'Hefnawy|Amr|A|', 'Hartmann|Rolf W|RW|', 'Engel|Matthias|M|', 'Piazza|Gary A|GA|', 'Abadi|Ashraf H|AH|']
D054706:Cyclic Nucleotide Phosphodiesterases, Type 5 D004305:Dose-Response Relationship, Drug D055808:Drug Discovery D006801:Humans D015394:Molecular Structure D058986:Phosphodiesterase 5 Inhibitors D011720:Pyrazoles D013329:Structure-Activity Relationship
Pyrazoline Celecoxib PDE5 PDE5 inhibitors cGMP elevation